Striatal Cannabinoid CB1 Receptor mRNA Expression Is Decreased in the Reserpine-Treated Rat Model of Parkinson's Disease

High levels of both endocannabinoids and endocannabinoid receptors are present in the basal ganglia. Attention has recently focused on the role of endocannabinoids in the control of movement and in movement disorders of basal ganglia origin such as Parkinson's disease. We investigated CB1 canna...

Full description

Saved in:
Bibliographic Details
Published in:Experimental neurology 2001-06, Vol.169 (2), p.400-406
Main Authors: Silverdale, M.A., McGuire, S., McInnes, A., Crossman, A.R., Brotchie, J.M.
Format: Article
Language:English
Subjects:
Animals
Autoradiography
Biological and medical sciences
Cannabinoid Receptor Modulators
cannabinoids
Cannabinoids - pharmacokinetics
CB1 receptor
Cerebral Cortex - metabolism
Corpus Striatum - metabolism
Corpus Striatum - pathology
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Disease Models, Animal
Gene Expression Regulation
Humans
In Situ Hybridization
Male
Medical sciences
Motor Activity
Neurology
Parkinson Disease - drug therapy
Parkinson Disease - pathology
Parkinson Disease - physiopathology
Parkinson's disease
rat
Rats
Rats, Sprague-Dawley
Receptors, Cannabinoid
Receptors, Drug - genetics
reserpine
Reserpine - pharmacology
RNA, Messenger - analysis
RNA, Messenger - genetics
Septum of Brain - metabolism
striatum
Sulfur Radioisotopes
Transcription, Genetic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High levels of both endocannabinoids and endocannabinoid receptors are present in the basal ganglia. Attention has recently focused on the role of endocannabinoids in the control of movement and in movement disorders of basal ganglia origin such as Parkinson's disease. We investigated CB1 cannabinoid receptor mRNA expression in the reserpine-treated rat model of Parkinson's disease using in situ hybridization. Reserpine treatment caused a topographically organized reduction in CB1 receptor mRNA expression in the striatum (ranging from 11.6% medially to 53.6% laterally and dorsally). No change in CB1 receptor mRNA expression was observed in the cerebral cortex or septum. This reduction in CB1 receptor mRNA expression may be secondary to increased endocannabinoid stimulation of the receptor as increased basal ganglia endocannabinoid levels have been shown to occur in this model of Parkinson's disease. The data support the idea that cannabinoid receptor antagonists may provide a useful treatment for the symptoms of Parkinson's disease.
ISSN:0014-4886
1090-2430
DOI:10.1006/exnr.2001.7649